Lundbeck announces successful completion of Parkinson's drug trials  

H. Lundbeck and Teva Pharmaceutical Industries complete phase III drug trials in Parkinson's disease patients

Danish pharmaceutical company H. Lundbeck and Israel's Teva Pharmaceutical Industries have announced the successful completion of two phase III clinical trials of rasagiline in patients with advanced Parkinson's disease. One trial was conducted in the US, the other in Europe, Israel and Argentina. On the basis of these results, applications will be made to approval authorities in both the US and EU in the second half of 2003 while research on rasagiline continues in relation to other neurological diseases. The news is reported on Lundbeck's website.


The development of rasagiline is part of a long-term strategic alliance for global co-development and European marketing between Lundbeck and Teva. Under the terms of the agreement Lundbeck will market rasagiline in Europe and in a number of overseas markets, in a joint effort with Teva, while Teva retains exclusive marketing rights in the rest of the world.


Teva develops, manufactures, and markets both generic and branded pharmaceuticals. The company's R&D focuses on developing novel drugs for diseases of the central nervous system. H. Lundbeck A/S specialises in the development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2002, the company's revenue was DKK 9.5 billion (USD 1.4 billion). The number of employees is approx. 5,100.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×